Q-omics provides the consensus-scored CCDC87 profile across patient tissues and cancer cell-line models. CCDC87 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, CCDC87 is differentially expressed in 14, with the highest sampling consensus in THCA. Additionally, CCDC87 RNA expression shows 17,791 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, THCA, and THYM as cancer lineages where CCDC87 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CCDC87 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CCDC87 survival associations across molecular data types. CCDC87 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CCDC87 RNA expression–survival associations across cancer types. High CCDC87 expression shows unfavorable associations in KIRP, LIHC and BLCA, but favorable associations in KIRC, PAAD and MESO. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for CCDC87 RNA expression.
This table summarizes CCDC87 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for CCDC87. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CCDC87 shows lower tumor expression in THCA and KICH and higher tumor expression in HNSC, LIHC, LUAD and BRCA. The THCA box plot shows higher CCDC87 RNA expression in normal versus tumor tissue (log2 FC = −1.707, t-test p < 0.001).
This table shows molecular features associated with CCDC87 in patient tissues and cancer cell lines. In patient samples, CCDC87 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, CCDC87 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OESOPHAGUS, while CRISPR and shRNA rows add functional-dependency signals in BREAST and OVARY.
